NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ROS, PI3K, ALK, Akt, PTEN, MMR, MSI-H, TMB-H, HER2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor, Serine Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients with brain metastasis may be eligible for Arm I of the study, but must also have tumors that are HER2+ & TMB-H or MSI-H
Exclusions: Patients with symptomatic or actively progressing CNS metastases; Patients with history of leptomeningeal disease, unless noted otherwise for a specific treatment arm of the study

Comments are closed.

Up ↑